by | Aug 14, 2023 | Uncategorized
Source: CureToday articles The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy. Read More
by | Aug 11, 2023 | Uncategorized
Source: CureToday articles Post Content Read More
by | Aug 10, 2023 | Uncategorized
The FDA granted accelerated approval to talquetamab-tgvs for treatment of certain patients with relapsed or refractory multiple myeloma.The indication authorizes use of the agent for adults who received at least four prior lines of therapy, including a proteasome...
by | Aug 10, 2023 | Uncategorized
Source: CureToday articles The FDA granted an accelerated approval for Talvey to treat patients with relapsed/refractory multiple myeloma. Read More
by | Jul 7, 2023 | Uncategorized
The FDA announced several regulatory actions the past few weeks.Here is an overview of decisions that may be relevant to your practice.1. The FDA issued a ”safe to proceed” for an investigational new drug application for NY-ESO-1 TCR/IL-15 NK (Syena) — an engineered...
by | Jun 28, 2023 | Uncategorized
Source: Cure Today articles Supervised exercise can help to improve the immune system for patients with myeloma, recent research showed. Read More
